PD-1 inhibitors (e.g., nivolumab, pembrolizumab) and CTLA-4 inhibitors (e.g., ipilimumab) are already approved for advanced ccRCC (4). Here, PDCD1 is linked to nonpapillary renal cell carcinoma.